NMTC
Neutral signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
NeuroOne Medical Technologies Corporation
- Nom
- NeuroOne Medical Technologies Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $8.4M
- Employés
- 18
- PDG
- David A. Rosa
- Site web
- https://nmtc1.com
- Marché
- ATHEBDMDCTSOECORHYPDMYO
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 33333 titres (~66999 USD)
- Insiders
- Wambeke David J.
- Total bought
-
$66,999
Avg buy (VWAP, 90d window) $2.01 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-27
- Last synced
-
2026-09-09 10:08:38
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-27 | Wambeke David J. | Buy · P | 33,333 | $2.01 | $66,999 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
NMTC shows meaningful operational progress with improving gross margins and a notable insider buy (~$67k) alongside a $6M NMTC financing catalyst, but the company remains unprofitable with persistent negative operating…
The first sentence of the analysis written for NMTC on 2026-09-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.44 · operating margin -35% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.3% | 31.3% | 23.4% | -41.4% | -54.9% | |
| Ebit Margin | -27.0% | -350.1% | -607.4% | -5842.0% | -5582.6% | |
| Ebitda Margin | -24.9% | -343.0% | -597.2% | -5772.7% | -5500.0% | |
| Operating Profit Margin | -34.9% | -344.3% | -612.3% | -5860.2% | -5735.9% | |
| Pretax Profit Margin | -29.8% | -356.7% | -607.4% | -5842.0% | -5584.3% | |
| Continuous Operations Profit Margin | -29.8% | -356.7% | -607.4% | -5842.0% | -5584.3% | |
| Net Profit Margin | -29.8% | -356.7% | -607.4% | -5842.0% | -5584.3% | |
| Bottom Line Profit Margin | -29.8% | -356.7% | -607.4% | -5842.0% | -5584.3% | |
| Current Ratio | 4.440 | 2.092 | 4.079 | 3.929 | 6.171 | |
| Quick Ratio | 3.473 | 0.902 | 3.116 | 3.702 | 6.088 | |
| Solvency Ratio | -0.901 | -2.654 | -6.310 | -3.070 | -7.079 | |
| Cash Ratio | 2.853 | 0.660 | 2.969 | 2.633 | 5.840 | |
| Price To Earnings Ratio | -9.870 | -2.152 | -1.369 | -2.683 | -4.247 | |
| Price To Earnings Growth Ratio | 0.123 | 0.074 | -0.431 | 0.083 | 0.067 | |
| Forward Price To Earnings Growth Ratio | 0.123 | 0.074 | -0.431 | 0.083 | 0.067 | |
| Price To Earnings Diluted Ratio | -9.870 | -2.152 | -1.369 | -2.683 | -4.247 | |
| Price To Earnings Diluted Growth Ratio | 0.123 | 0.074 | -0.431 | 0.083 | 0.067 | |
| Price To Book Ratio | 5.043 | 32.232 | 2.581 | 2.815 | 6.447 | |
| Price To Sales Ratio | 2.948 | 7.673 | 8.260 | 157.958 | 237.178 | |
| Price To Free Cash Flow Ratio | -12.220 | -2.380 | -1.215 | -3.469 | -4.873 | |
| Price To Operating Cash Flow Ratio | -12.572 | -2.406 | -1.251 | -3.596 | -4.911 | |
| Debt To Assets Ratio | 0.025 | 0.048 | 0.023 | 0.016 | 0.040 | |
| Debt To Equity Ratio | 0.038 | 0.316 | 0.030 | 0.021 | 0.048 | |
| Debt To Capital Ratio | 0.036 | 0.240 | 0.029 | 0.021 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.525 | 6.533 | 1.296 | 1.335 | 1.211 | |
| Working Capital Turnover Ratio | 2.340 | 0.870 | 0.268 | 0.023 | 0.045 | |
| Operating Cash Flow Ratio | -1.232 | -4.975 | -7.189 | -2.427 | -7.280 | |
| Operating Cash Flow Sales Ratio | -0.235 | -3.189 | -6.600 | -43.930 | -48.291 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.029 | 1.011 | 1.030 | 1.037 | 1.008 | |
| Debt Service Coverage Ratio | -9.009 | -51.716 | 0.000 | 0.000 | -3,209.297 | |
| Interest Coverage Ratio | -12.652 | -51.912 | 0.000 | 0.000 | -3,346.941 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.634 | -42.327 | -69.885 | -37.061 | -27.252 | |
| Capital Expenditure Coverage Ratio | -34.710 | -91.615 | -33.549 | -27.321 | -128.249 | |
| Dividend Paid And Capex Coverage Ratio | -34.710 | -91.615 | -33.549 | -27.321 | -128.249 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.757 | -2.136 | -0.942 | -1.931 | -3.640 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.3% | ▲36.0% | ▲62.2% |
| Ebit Margin | -27.0% | ▲323.1% | ▲2454.8% |
| Ebitda Margin | -24.9% | ▲318.1% | ▲2422.7% |
| Operating Profit Margin | -34.9% | ▲309.3% | ▲2482.6% |
| Pretax Profit Margin | -29.8% | ▲326.9% | ▲2454.2% |
| Continuous Operations Profit Margin | -29.8% | ▲326.9% | ▲2454.2% |
| Net Profit Margin | -29.8% | ▲326.9% | ▲2454.2% |
| Bottom Line Profit Margin | -29.8% | ▲326.9% | ▲2454.2% |
| Current Ratio | 4.440 | ▲2.348 | ▲0.298 |
| Quick Ratio | 3.473 | ▲2.572 | ▲0.017 |
| Solvency Ratio | -0.900 | ▲1.754 | ▲3.102 |
| Cash Ratio | 2.853 | ▲2.193 | ▼-0.138 |
| Price To Earnings Ratio | -9.870 | ▼-7.718 | ▼-5.806 |
| Price To Earnings Growth Ratio | 0.123 | ▲0.049 | ▲0.140 |
| Forward Price To Earnings Growth Ratio | 0.123 | ▲0.049 | ▲0.140 |
| Price To Earnings Diluted Ratio | -9.870 | ▼-7.718 | ▼-5.806 |
| Price To Earnings Diluted Growth Ratio | 0.123 | ▲0.049 | ▲0.140 |
| Price To Book Ratio | 5.043 | ▼-27.188 | ▼-4.780 |
| Price To Sales Ratio | 2.948 | ▼-4.724 | ▼-79.855 |
| Price To Free Cash Flow Ratio | -12.220 | ▼-9.839 | ▼-7.388 |
| Price To Operating Cash Flow Ratio | -12.572 | ▼-10.166 | ▼-7.624 |
| Debt To Assets Ratio | 0.025 | ▼-0.024 | ▼-0.006 |
| Debt To Equity Ratio | 0.038 | ▼-0.279 | ▼-0.053 |
| Debt To Capital Ratio | 0.036 | ▼-0.204 | ▼-0.038 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.525 | ▼-5.008 | ▼-0.855 |
| Working Capital Turnover Ratio | 2.340 | ▲1.470 | ▲1.631 |
| Operating Cash Flow Ratio | -1.232 | ▲3.744 | ▲3.389 |
| Operating Cash Flow Sales Ratio | -0.234 | ▲2.954 | ▲20.215 |
| Free Cash Flow Operating Cash Flow Ratio | 1.029 | ▲0.018 | ▲0.006 |
| Debt Service Coverage Ratio | -9.009 | ▲42.707 | ▲644.995 |
| Interest Coverage Ratio | -12.652 | ▲39.260 | ▲669.649 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -10.634 | ▲31.693 | ▲26.798 |
| Capital Expenditure Coverage Ratio | -34.710 | ▲56.905 | ▲28.379 |
| Dividend Paid And Capex Coverage Ratio | -34.710 | ▲56.905 | ▲28.379 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.757 | ▼-7.621 | ▼-6.076 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $35.7M | $26.5M | $16.1M | $27.0M | $42.3M | |
| Enterprise value | $29.4M | $25.3M | $11.0M | $19.1M | $35.7M | |
| EV / Sales | 2.43x | 7.33x | 5.63x | 111.47x | 200.21x | |
| EV / Op. cash flow | -10.35x | -2.30x | -0.85x | -2.54x | -4.15x | |
| EV / Free cash flow | -10.06x | -2.27x | -0.83x | -2.45x | -4.11x | |
| EV / EBITDA | -9.76x | -2.14x | -0.94x | -1.93x | -3.64x | |
| Net debt / EBITDA | 2.09x | 0.10x | 0.44x | 0.81x | 0.67x | |
| Current ratio | 4.44x | 2.09x | 4.08x | 3.93x | 6.17x | |
| Income quality | 0.79x | 0.89x | 1.09x | 0.75x | 0.86x | |
| Graham net-net | $1 | -$0 | $1 | $3 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 110.2% | 101.9% | 100.0% | 100.0% | 100.0% | |
| Working capital | $7.9M | $2.4M | $5.5M | $9.1M | $6.1M | |
| Invested capital | $8.5M | $3.2M | $6.3M | $9.7M | $6.8M | |
| Return on assets | -33.4% | -229.4% | -146.5% | -78.0% | -125.3% | |
| Operating ROA | -52.3% | -176.5% | -114.3% | -96.6% | -160.9% | |
| Return on tangible assets | -33.6% | -232.3% | -148.1% | -78.7% | -127.5% | |
| Return on equity | -51.0% | -1498.5% | -189.8% | -104.1% | -151.8% | |
| Return on invested capital | -49.1% | -368.9% | -185.8% | -102.3% | -148.7% | |
| Return on capital employed | -49.8% | -376.6% | -189.6% | -103.2% | -151.2% | |
| Earnings yield | -10.1% | -46.5% | -73.5% | -37.0% | -23.5% | |
| Free cash flow yield | -8.2% | -42.0% | -82.3% | -28.8% | -20.5% | |
| Capex / Op. cash flow | -2.9% | -1.1% | -3.0% | -3.7% | -0.8% | |
| Capex / Depreciation | 31.2% | 48.7% | 192.8% | 232.0% | 83.1% | |
| Capex / Sales | 0.7% | 3.5% | 19.7% | 160.8% | 37.7% | |
| SG&A / Sales | 61.0% | 228.8% | 354.7% | 4077.5% | 3514.1% | |
| R&D / Sales | 41.2% | 146.7% | 355.5% | 2879.9% | 2203.3% | |
| Stock comp / Sales | 10.5% | 38.9% | 56.6% | 553.4% | 1006.6% | |
| Intangibles / Total assets | 0.4% | 1.3% | 1.1% | 0.9% | 1.7% | |
| Days sales outstanding | 38d | 19d | 0d | 71d | 99d | |
| Days payables outstanding | 93d | 158d | 167d | 1399d | 700d | |
| Operating cycle | 244d | 424d | 421d | 1134d | 229d | |
| Cash conversion cycle | 150d | 266d | 254d | -266d | -471d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-18 $6 Million in New Markets Tax Credit Financing for the Acquisition, Renovation, and Equipping of a Tractor Assembly Facility in Monroeville, AL $6 Million in New Markets Tax Credit Financing for the Acquisition, Renovation, and Equipping of a Tractor Assembly Facility in Monroeville, AL
- 2026-08-13 NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript